Monoclonal Antibodies for Kell Antigen Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies fail to provide sufficient units of compatible red blood cells for alloimmunized patients, leading to morbidity and mortality due to incompatible blood transfusions, and there is no prophylaxis available for antigens like Kell, Kidd, and Duffy, which can result in hemolytic transfusion reactions and hemolytic disease of the fetus and newborn.
Innovation Solution
Development of monoclonal antibodies that recognize single amino acid polymorphisms on red blood cell surface antigens, specifically targeting the Kell blood group system, to block hemolytic transfusion reactions by binding to antigens and preventing recipient antibodies from destroying transfused red blood cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prematching to select matched blood group antigens is performed, then hemolytic transfusion reactions are prevented, but the process is costly and delays blood delivery
Solution Approach 1:
The patent applies preliminary action by administering prophylactic antibodies (such as anti-Kell antibodies) to alloimmunized patients before they receive red blood cell transfusions. This pre-treatment blocks the antigen sites on donor RBCs, preventing the patient's alloantibodies from binding and causing hemolysis. By performing this protective action in advance, the need for time-consuming prematching procedures is eliminated, allowing for immediate blood delivery while maintaining high reliability in preventing hemolytic transfusion reactions.
2Reliability
If prematching to select matched blood group antigens is performed, then hemolytic transfusion reactions are prevented, but the process is costly
Solution Approach 1:
The patent applies the taking out principle by extracting the critical protective function from the complex prematching process. Instead of performing extensive antigen matching to identify compatible blood units, the invention extracts and administers specific prophylactic antibodies that directly block the harmful antigen-antibody interactions. This extraction of the essential protective mechanism eliminates the need for costly matching procedures while maintaining reliable prevention of hemolytic transfusion reactions.
3Reliability
If monoclonal antibodies are developed to recognize single amino acid polymorphisms, then specific antigen-antibody interactions are blocked, but the complexity of antibody development increases
Solution Approach 1:
The patent applies the copying principle by using monoclonal antibody technology to create identical, standardized antibody products that recognize specific amino acid polymorphisms on red blood cell antigens. These monoclonal antibodies are produced in large quantities with consistent specificity and affinity, allowing them to reliably block harmful antigen-antibody interactions. The standardized copying of successful antibody designs across different antigen targets reduces overall development complexity while maintaining high reliability in preventing hemolytic transfusion reactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively prevent or reduce hemolytic transfusion reactions by blocking antigen-antibody interactions, ensuring compatible blood transfusions and reducing the risk of hemolytic disease of the fetus and newborn.
Implementation Method 1
monoclonal antibodies that recognize single amino acid polymorphisms on red blood cell surface antigens, specifically targeting the Kell blood group system, to block hemolytic transfusion reactions by binding to antigens and preventing recipient antibodies from destroying transfused red blood cells
Data Source
AI summary
Compositions and methods of using antibodies that are able to recognize single amino acid polymorphisms in a protein are provided. Compositions are disclosed which may be used for blood typing or to block hemolytic transfusion reactions and/or hemolytic disease of the fetus and newborn.